|TNFi monoclonal antibodies|Infliximab, adalimumab, certolizumab, golimumab.|
|Biologics|TNFi, abatacept, rituximab, sarilumab, tocilizumab, ustekinumab, secukinumab, ixekizumab.**|
|High-quality evidence|Studies that provide high confidence in the effect estimate, and new data from future studies are thought unlikely to change the effect.|
|Moderate-quality evidence|Studies that provide confidence that the true effect is likely to be close to the estimate but could be substantially different.|